We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+0.2%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$20.9B
AUM Growth
-$1.94B
Cap. Flow
-$1.04B
Cap. Flow %
-4.99%
Top 10 Hldgs %
40.27%
Holding
168
New
18
Increased
43
Reduced
28
Closed
22

Top Buys

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$381M
2
MSFT icon
Microsoft
MSFT
+$266M
3
CRM icon
Salesforce
CRM
+$235M
4
K
Kellanova
K
+$186M
5
ARMK icon
Aramark
ARMK
+$178M

Top Sells

Rank Stock Value
1
ABNB icon
Airbnb
ABNB
+$319M
2
HCP
HashiCorp, Inc. Class A Common Stock
HCP
+$221M
3
AON icon
Aon
AON
+$181M
4
BMY icon
Bristol-Myers Squibb
BMY
+$180M
5
HES
Hess
HES
+$150M

Sector Composition

Rank Sector Weight
1 Healthcare 37.95%
2 Technology 14.96%
3 Financials 12.32%
4 Communication Services 7.9%
5 Industrials 5.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VYGR icon
76
Voyager Therapeutics
VYGR
$201M
$8.69M 0.04%
2,570,700
– –
BBOT
77
BridgeBio Oncology
BBOT
$747M
$6.78M 0.03%
600,000
– –
TNGX icon
78
Tango Therapeutics
TNGX
$4.41B
$6.32M 0.03%
4,610,930
+610,930
+15% +$1.5M
GMED icon
79
Globus Medical
GMED
$11.2B
$6.08M 0.03%
83,000
+79,400
+2,206% +$6.56M
SWTX
80
DELISTED
SpringWorks Therapeutics
SWTX
$5.21M 0.03%
+118,000
New +$5.43M
ZYME icon
81
Zymeworks
ZYME
$1.67B
$4.76M 0.02%
400,000
-929,974
-70% -$12.7M
RXST icon
82
RxSight
RXST
$260M
$4.42M 0.02%
+175,000
New +$5.2M
LBRDA icon
83
Liberty Broadband Class A
LBRDA
$5.16B
$4.25M 0.02%
+50,000
New +$3.99M
VERV
84
DELISTED
Verve Therapeutics
VERV
$4.17M 0.02%
+912,000
New +$6.11M
SMC
85
Summit Midstream
SMC
$419M
$1.97M 0.01%
58,214
– –
ALVO icon
86
Alvotech
ALVO
$1.29B
$1.93M 0.01%
199,675
– –
GATE
87
DELISTED
Marblegate Acquisition Corp. Class A Common Stock
GATE
$1.66M 0.01%
150,000
– –
PRME icon
88
Prime Medicine
PRME
$559M
$1.49M 0.01%
750,000
– –
SIMO icon
89
Silicon Motion
SIMO
$8.68B
$1.48M 0.01%
29,298
-385,702
-93% -$20.9M
LIVN icon
90
LivaNova
LIVN
$4.2B
$1.45M 0.01%
+37,000
New +$1.66M
JANX icon
91
Janux Therapeutics
JANX
$967M
$1.3M 0.01%
48,000
– –
BDSX icon
92
Biodesix
BDSX
$248M
$1.16M 0.01%
92,965
-97,606
-51% -$1.87M
MDGL icon
93
Madrigal Pharmaceuticals
MDGL
$11.8B
$1.1M 0.01%
3,319
– –
TVRD
94
Tvardi Therapeutics
TVRD
$23.4M
$658K ﹤0.01%
43,228
– –
FBRX icon
95
Forte Biosciences
FBRX
$1.57B
$547K ﹤0.01%
70,429
+35,429
+101% +$418K
AXSM icon
96
Axsome Therapeutics
AXSM
$10.9B
$467K ﹤0.01%
4,000
– –
ARQT icon
97
Arcutis Biotherapeutics
ARQT
$3.18B
$407K ﹤0.01%
26,000
– –
PGNY icon
98
Progyny
PGNY
$2.2B
$402K ﹤0.01%
18,000
– –
BTSG icon
99
BrightSpring Health Services
BTSG
$12.4B
$398K ﹤0.01%
22,000
– –
ROIV icon
100
Roivant Sciences
ROIV
$26.2B
$373K ﹤0.01%
37,000
– –
2 3
4
5 6

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Farallon Capital Management held 168 positions worth $20.9B, down 8.5% from $22.8B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Farallon Capital Management withdrew a net $1.04B in Q1 2025, closing 22 positions and reducing 28 holdings. Its most notable exit was Airbnb, an estimated $319M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 34% a quarter earlier, followed by Technology and Financials.

Against the trend, Farallon Capital Management opened a new position in Intra-Cellular Therapies Inc. worth $403M.

  • Farallon Capital Management's largest Q1 2025 buy was Intra-Cellular Therapies Inc.: 3,055,000 shares worth $403M.
  • Farallon Capital Management added most to Microsoft in Q1 2025, an estimated $266M increase.
  • Farallon Capital Management's biggest Q1 2025 reduction was Aon, cutting an estimated $181M.
  • Farallon Capital Management fully exited Airbnb in Q1 2025, selling an estimated $319M.
  • Farallon Capital Management's ten largest holdings make up 40% of its $20.9B portfolio in Q1 2025.
  • Farallon Capital Management opened 18 new positions and closed 22 in Q1 2025.
  • Farallon Capital Management's portfolio value fell 8.5% quarter-over-quarter to $20.9B.

Based on Farallon Capital Management's 13F filing for Q1 2025, filed 15 May 2025.